🇺🇸 FDA
Company

TG

TG THERAPEUTICS, INC.

TGTX pharma USA

Quick answer

TG is a pharma company (TGTX) headquartered in NEW YORK, NY, USA with 24 tracked pipeline programs.

Pipeline (24)

project

Obinutuzumab

Chronic Lymphocytic Leukemia

Phase 3 · mab · terminated

1 trials project

Ublituximab

Chronic Lymphocytic Leukemia

Phase 3 · small_molecule · completed

5 trials project

Ublituximab

Relapsing Multiple Sclerosis (RMS)

Phase 3 · mab · active

3 trials project

Ublituximab

Relapsing Multiple Sclerosis

Phase 3 · small_molecule · active

3 trials project

Ublituximab

Diffuse Large B-Cell Lymphoma

Phase 3 · mab · terminated

1 trials project

Acalabrutinib

Chronic Lymphocytic Leukemia

Phase 2 · small_molecule · active

1 trials project

Pembrolizumab

Hodgkin's Lymphoma

Phase 2 · mab · terminated

1 trials project

TGR-1202

Follicular Lymphoma

Phase 2 · small_molecule · terminated

1 trials project

TGR-1202

Chronic Lymphocytic Leukemia

Phase 2 · small_molecule · terminated

1 trials project

Ublituximab

Non-Hodgkins Lymphoma

Phase 2 · small_molecule · completed

2 trials project

Ublituximab

Follicular Lymphoma

Phase 2 · small_molecule · terminated

1 trials project

Ublituximab

Relapsing Remitting Multiple Sclerosis

Phase 2 · mab · completed

1 trials project

Ublituximab

Autoimmune Disorders

Phase 2 · small_molecule · active

1 trials project

Umbralisib

Marginal Zone Lymphoma

Phase 2 · small_molecule · completed

1 trials project

Umbralisib

Lymphoma

Phase 2 · small_molecule · terminated

1 trials project

Umbralisib

Chronic Lymphocytic Leukemia

Phase 2 · small_molecule · completed

4 trials project

Venetoclax

Chronic Lymphocytic Leukemia

Phase 2 · small_molecule · terminated

1 trials project

Azercabtagene zapreleucel (azer-cel)

B-cell Mediated Autoimmune Disorders

Phase 1 · small_molecule · active

1 trials project

Cosibelimab

B-cell Non Hodgkin Lymphoma

Phase 1 · small_molecule · terminated

1 trials project

NM1F Injection

Ovarian Cancer

Phase 1 · small_molecule · active

1 trials project

TG-1701

Non Hodgkin Lymphoma

Phase 1 · small_molecule · terminated

1 trials project

TG-1801

CLL

Phase 1 · mab · terminated

1 trials project

TG-1801

B-Cell Lymphoma

Phase 1 · small_molecule · completed

1 trials project

TGI-5

CRC (Colorectal Cancer)

Phase 1 · small_molecule · active

1 trials

Drugs (1)

drug

ublituximab-xiiy

BRIUMVI

Patents (7)

patent

US 11965032

Anti-CD20 antibody compositions

Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11884740

Anti-CD20 antibody compositions

Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11814439

Anti-CD20 antibody compositions

Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11807689

Anti-CD20 antibody compositions

Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10966977

Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK

Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10729768

Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 9694071

Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

Expires Mon Jun 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)